W Zhang, G Nuki, RW Moskowitz, S Abramson… - Osteoarthritis and …, 2010 - Elsevier
OBJECTIVE: To update evidence for available therapies in the treatment of hip and knee osteoarthritis (OA) and to examine whether research evidence has changed from 31 …
PRESCRIPTION DRUGS ARE THE THIRD LEADING CAUSE OF DEATH AFTER HEART DISEASE AND CANCER. In his latest ground-breaking book, Peter C Gotzsche exposes the …
W Zhang, RW Moskowitz, G Nuki, S Abramson… - Osteoarthritis and …, 2008 - Elsevier
PURPOSE: To develop concise, patient-focussed, up to date, evidence-based, expert consensus recommendations for the management of hip and knee osteoarthritis (OA), which …
Background Randomised trials have highlighted the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) in high doses and sometimes atypical settings. Here, we …
American Geriatrics Society Panel on the … - Pain …, 2009 - academic.oup.com
Pain is a complex phenomenon caused by noxious sensory stimuli or neuropathological mechanisms. An individual's memories, expectations, and emotions modify the experience …
Background There are several guidelines addressing the issues around the use of NSAIDs. However, none has specifically addressed the upper versus lower gastrointestinal (GI) risk …
W Zhang, RW Moskowitz, G Nuki, S Abramson… - Osteoarthritis and …, 2007 - Elsevier
PURPOSE: As a prelude to developing updated, evidence-based, international consensus recommendations for the management of hip and knee osteoarthritis (OA), the Osteoarthritis …
ContextEvidence that rofecoxib increases the risk of myocardial infarction has led to scrutiny of other nonsteroidal anti-inflammatory drugs (NSAIDs). Regulatory agencies have provided …
RA associates with an increased burden of cardiovascular disease, which is at least partially attributed to classical risk factors such as hypertension (HT) and dyslipidaemia. HT is highly …